Insider Trading November 18, 2026 11:01 PM

Revolution Medicines Insider Sale: Stephen Kelsey Offloads $4.5 Million in Stock

Senior Advisor exercises options and sells shares under pre-arranged trading plan, leaving him with 286,307 shares and 108,640 options.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
RVMD

Stephen Michael Kelsey, Senior Advisor to the CEO of Revolution Medicines (NASDAQ: RVMD), sold 27,160 shares for approximately $4.56 million on November 16, 2026, with prices ranging from $166.14 to $171.65. The sale followed the exercise of options at $18.56 per share and was executed under a 10b5-1 trading plan adopted on August 17, 2026. After the transactions, Kelsey directly holds 286,307 shares, including 65,613 restricted stock units, and beneficially owns 108,640 derivative securities in the form of stock options. The stock, currently at $159.82, is down 9.4% over the past week but has gained 127% over the past year and over 100% year-to-date. In other news, Revolution Medicines reported Q3 2026 net product sales of $197.6 million for RASONQUE and a net loss of $407.5 million, while the European Commission approved RASONQUE for metastatic pancreatic ductal adenocarcinoma. Analyst firms H.C. Wainwright and Stifel maintain Buy ratings with price targets of $350 and $230, respectively.

Revolution Medicines Insider Sale: Stephen Kelsey Offloads $4.5 Million in Stock
RVMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Stephen Kelsey, Senior Advisor to the CEO, sold 27,160 shares for about $4.56 million under a 10b5-1 trading plan, after exercising options at $18.56 per share.
  • Revolution Medicines reported Q3 2026 net product sales of $197.6 million for RASONQUE and a net loss of $407.5 million, while the European Commission approved RASONQUE for metastatic pancreatic ductal adenocarcinoma.
  • Analyst firms H.C. Wainwright and Stifel maintain Buy ratings with price targets of $350 and $230, respectively, citing confidence in the company's outlook.

Revolution Medicines, Inc. (NASDAQ: RVMD) disclosed that Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer, sold 27,160 shares of common stock on November 16, 2026. The transactions totaled approximately $4,559,209, with per-share prices ranging from $166.14 to $171.65. The sales were executed pursuant to a pre-arranged 10b5-1 trading plan that Kelsey adopted on August 17, 2026.

Prior to the sales, Kelsey exercised options to acquire 27,160 shares of common stock at $18.56 per share, for a total cost of $504,089. These options were fully vested. Following the transactions, Kelsey directly holds 286,307 shares of Revolution Medicines common stock, a position that includes 65,613 restricted stock units. In addition, he beneficially owns 108,640 derivative securities in the form of stock options.

The sale comes as Revolution Medicines' stock trades at $159.82, down 9.4% over the past week. Despite that recent pullback, the shares have delivered a 127% return over the past year, with a year-to-date gain exceeding 100%. According to InvestingPro analysis, Revolution Medicines appears undervalued at current levels, with the stock trading below its Fair Value.

In other recent developments, Revolution Medicines reported its first quarter of product revenue following the U.S. launch of RASONQUE, with net product sales reaching $197.6 million in the third quarter of 2026. The company recorded a net loss of $407.5 million due to increased spending on commercialization and late-stage development, yet investors focused on the rapid revenue growth. Additionally, the European Commission has approved RASONQUE for the treatment of metastatic pancreatic ductal adenocarcinoma, expanding its potential market.

Analyst firms have shown confidence in Revolution Medicines. H.C. Wainwright reiterated a Buy rating and set a price target of $350.00. Stifel also maintained a Buy rating, with a price target of $230.00, and noted the stock as an attractive buying opportunity below $200 per share. Stifel believes that the stock's potential upside depends on opportunities beyond pancreatic cancer. These developments highlight significant progress for Revolution Medicines in both the U.S. and European markets.

Risks

  • The stock's recent 9.4% weekly decline and the insider sale could signal short-term pressure, though the sale was pre-planned and the stock has strong longer-term gains.
  • The company's net loss of $407.5 million reflects heavy spending on commercialization and late-stage development, which may weigh on financial results if revenue growth does not offset expenses.
  • Stifel notes that the stock's potential upside depends on opportunities beyond pancreatic cancer, leaving the valuation sensitive to progress in other areas.

More from Insider Trading

Jack Henry Accounting Chief Swearingen Sells $159,695 in Stock, Gifts Shares Nov 18, 2026 PubMatic Accounting Chief Gimbel Offloads $27,887 in Shares to Cover RSU Tax Bill Nov 18, 2026 Constellation Brands 10% Holder AJB Business Holdings Offloads 75,000 Shares for $10.88 Million Nov 18, 2026 Figma Director Radakovich Offloads $395K in Stock Near 52-Week Low Nov 18, 2026 Constellation Brands Insider Zachary Stern Offloads $10.88 Million in Class A Shares Nov 18, 2026